SOURCE: The Bedford Report

The Bedford Report

August 05, 2011 08:16 ET

MultiCell Technology and Aastrom Biosciences Aim to Shatter Stem Cell Myths

The Bedford Report Provides Equity Research on MultiCell Technologies and Aastrom Biosciences

NEW YORK, NY--(Marketwire - Aug 5, 2011) - With Americans spending in excess of $300 billion annually on drugs which typically only treat disease symptoms, regenerative therapies are garnering increased support. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on MultiCell Technology, Inc. (OTCBB: MCET) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Access to the full company reports can be found at:

www.bedfordreport.com/MCET

www.bedfordreport.com/ASTM

Embryonic stems cell research suffers on-again, off-again bans on US federal funding. Since Obama took office, funding has been less sporadic. Earlier this spring a US appeals court ruled that the Obama administration can continue using federal tax dollars to fund human embryonic stem cell research.

Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.

The Bedford Report releases stock research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Earlier this year MultiCell Technologies was granted a patent relating to the isolation and use of human liver stem cells to treat liver disease. The patent describes methods to isolate and use human liver stem cells to treat degenerative liver diseases, or inherited deficiencies of liver function. According to MCET, "The role of liver stem cells in the carcinogenic process has led researchers to hypothesize that primary liver cancer arises by maturation arrest of liver stem cells."

Aastrom Biosciences uses stem cells derived from adults. Aastrom is developing a personalized stem cell therapy for the treatment of critical limb ischemia (CLI). Patients with chronic CLI have obstructed arteries and reduced blood flow in the arms and legs, which can lead to open wounds and amputation in the most severe cases.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.

Contact Information